Anavex Life Sciences Corp. (AVXL) Posts Quarterly Earnings Results, Hits Estimates
Anavex Life Sciences Corp. (NASDAQ:AVXL) posted its earnings results on Monday. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09), Bloomberg Earnings reports.
Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) opened at 3.74 on Wednesday. The stock’s market cap is $154.75 million. Anavex Life Sciences Corp. has a one year low of $2.43 and a one year high of $6.64. The company has a 50-day moving average of $4.97 and a 200 day moving average of $5.44.
Several brokerages recently commented on AVXL. Noble Financial reissued a “buy” rating on shares of Anavex Life Sciences Corp. in a report on Wednesday. ValuEngine raised shares of Anavex Life Sciences Corp. from a “sell” rating to a “hold” rating in a report on Thursday, August 3rd. Maxim Group set a $15.00 price target on shares of Anavex Life Sciences Corp. and gave the stock a “buy” rating in a report on Monday. Finally, Zacks Investment Research lowered shares of Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $11.94.
WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/09/anavex-life-sciences-corp-avxl-posts-quarterly-earnings-results-hits-estimates.html.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.